Achaogen, Inc., a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKAO
Previous Symbol
CUSIPN/A
Phone650-800-3636
Debt
Debt-to-Equity Ratio1.00
Current Ratio2.54
Quick Ratio2.52
Price-To-Earnings
Trailing P/E Ratio-0.51
Forward P/E Ratio-0.43
P/E GrowthN/A
Sales & Book Value
Annual Sales$11.18 million
Price / Sales6.68
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.88 per share
Price / Book0.56
Profitability
EPS (Most Recent Fiscal Year)($3.17)
Net Income$-125,610,000.00
Net Margins-2,045.86%
Return on Equity-214.74%
Return on Assets-106.90%
Miscellaneous
Employees230
Outstanding Shares46,120,000
Market Cap$83.02 million
OptionableOptionable
Achaogen (NASDAQ:AKAO) Frequently Asked Questions
What is Achaogen's stock symbol?
Achaogen trades on the NASDAQ under the ticker symbol "AKAO."
How were Achaogen's earnings last quarter?
Achaogen Inc (NASDAQ:AKAO) issued its quarterly earnings data on Thursday, November, 8th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.96) by $0.08. The biopharmaceutical company earned $2 million during the quarter, compared to the consensus estimate of $3.80 million. Achaogen had a negative net margin of 2,045.86% and a negative return on equity of 214.74%. View Achaogen's Earnings History.
When is Achaogen's next earnings date?
What price target have analysts set for AKAO?
11 analysts have issued 12 month price targets for Achaogen's stock. Their predictions range from $3.00 to $22.00. On average, they expect Achaogen's share price to reach $10.8571 in the next twelve months. This suggests a possible upside of 570.2% from the stock's current price. View Analyst Price Targets for Achaogen.
What is the consensus analysts' recommendation for Achaogen?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achaogen in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Achaogen.
What are Wall Street analysts saying about Achaogen stock?
Here are some recent quotes from research analysts about Achaogen stock:
- 1. HC Wainwright analysts commented, "916-3963, POS Risk-adj value Full value Rating ZEMDRI – U.S. 100% $1.92 $1.92 Shares outstanding 46,120 2018 ZEMDRI – EU 35% $0.64 $1.83 Current share price $2.25 Discount rate 18.0% C-Scape – U.S." (11/12/2018)
- 2. Mizuho analysts commented, "We currently project a cash runway into mid-2019. In our valuation, we assume a $200 mil capital raise at $3.50/share in 1Q19 and we also increased our discount rate from 10% to 17% to reflect significantly increased risks. Our PT goes to $8." (11/6/2018)
- 3. According to Zacks Investment Research, "Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California. " (10/17/2018)
Has Achaogen been receiving favorable news coverage?
Media stories about AKAO stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Achaogen earned a daily sentiment score of -1.1 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an effect on the stock's share price in the next few days.
Who are some of Achaogen's key competitors?
Some companies that are related to Achaogen include Evolus (EOLS), Marker Therapeutics (MRKR), Verastem (VSTM), Concert Pharmaceuticals (CNCE), Evelo Biosciences (EVLO), Aratana Therapeutics (PETX), Minerva Neurosciences (NERV), Albireo Pharma (ALBO), Seres Therapeutics (MCRB), Avid Bioservices (CDMO), OptiNose (OPTN), Syros Pharmaceuticals (SYRS), Athersys (ATHX), MannKind (MNKD) and Merus (MRUS).
Who are Achaogen's key executives?
Achaogen's management team includes the folowing people:
- Mr. Blake Wise, CEO & Director (Age 47)
- Mr. Gary Loeb, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 48)
- Ms. Zeryn Sarpangal, CFO & Principal Accounting Officer (Age 38)
- Ms. Elizabeth Bhatt, Chief Bus. Officer & COO (Age 50)
- David Arrington, VP of Investor Relations & Corp. Communications
Who are Achaogen's major shareholders?
Achaogen's stock is owned by many different of institutional and retail investors. Top institutional investors include Foresite Capital Management III LLC (5.15%), Vanguard Group Inc. (3.63%), Vanguard Group Inc (3.63%), AXA (2.00%), Gabelli Funds LLC (0.68%) and JPMorgan Chase & Co. (0.65%). Company insiders that own Achaogen stock include Blake Wise, Equity Opportunities Iv Growth, Gary Loeb, Ian Friedland, Janet Dorling, Kenneth J Hillan, Robert W Duggan, Tobin Schilke and Zeryn Sarpangal. View Institutional Ownership Trends for Achaogen.
Which institutional investors are selling Achaogen stock?
AKAO stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management III LLC, Renaissance Technologies LLC and Wells Fargo & Company MN. Company insiders that have sold Achaogen company stock in the last year include Blake Wise, Gary Loeb, Janet Dorling, Kenneth J Hillan and Tobin Schilke. View Insider Buying and Selling for Achaogen.
Which institutional investors are buying Achaogen stock?
AKAO stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., JPMorgan Chase & Co., AXA, SG Americas Securities LLC, Vanguard Group Inc, Vanguard Group Inc., Teton Advisors Inc. and Gabelli Funds LLC. Company insiders that have bought Achaogen stock in the last two years include Equity Opportunities Iv Growth and Robert W Duggan. View Insider Buying and Selling for Achaogen.
How do I buy shares of Achaogen?
Shares of AKAO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Achaogen's stock price today?
One share of AKAO stock can currently be purchased for approximately $1.62.
How big of a company is Achaogen?
Achaogen has a market capitalization of $83.02 million and generates $11.18 million in revenue each year. The biopharmaceutical company earns $-125,610,000.00 in net income (profit) each year or ($3.17) on an earnings per share basis. Achaogen employs 230 workers across the globe.
What is Achaogen's official website?
How can I contact Achaogen?
Achaogen's mailing address is 1 TOWER PLACE SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-800-3636 or via email at [email protected]
MarketBeat Community Rating for Achaogen (NASDAQ AKAO)
MarketBeat's community ratings are surveys of what our community members think about Achaogen and other stocks. Vote "Outperform" if you believe AKAO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKAO will underperform the S&P 500 over the long term. You may vote once every thirty days.
